S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Bargain in Today's Market (SHOCKING) (Ad)pixel
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Bargain in Today's Market (SHOCKING) (Ad)pixel
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Bargain in Today's Market (SHOCKING) (Ad)pixel
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Bargain in Today's Market (SHOCKING) (Ad)pixel
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
NASDAQ:FOLD

Amicus Therapeutics - FOLD Stock Forecast, Price & News

$12.36
-0.18 (-1.44%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.06
$12.62
50-Day Range
$7.63
$12.54
52-Week Range
$5.91
$12.73
Volume
2.90 million shs
Average Volume
3.50 million shs
Market Capitalization
$3.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.25

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
23.4% Upside
$15.25 Price Target
Short Interest
Healthy
7.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.00mentions of Amicus Therapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$1.24 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.88) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

706th out of 1,098 stocks

Pharmaceutical Preparations Industry

344th out of 536 stocks

FOLD stock logo

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group assumed coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a "neutral" rating for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $15.25.

Amicus Therapeutics Price Performance

NASDAQ:FOLD traded down $0.27 during mid-day trading on Tuesday, hitting $12.27. The company's stock had a trading volume of 172,350 shares, compared to its average volume of 3,080,933. The company has a market capitalization of $3.44 billion, a price-to-earnings ratio of -12.67 and a beta of 0.96. The company has a current ratio of 3.02, a quick ratio of 2.90 and a debt-to-equity ratio of 2.25. Amicus Therapeutics has a fifty-two week low of $5.91 and a fifty-two week high of $12.73. The stock has a fifty day moving average of $10.05 and a 200-day moving average of $9.04.

Amicus Therapeutics (NASDAQ:FOLD - Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. Amicus Therapeutics had a negative return on equity of 102.55% and a negative net margin of 87.50%. During the same period in the previous year, the firm posted ($0.19) earnings per share. As a group, equities analysts forecast that Amicus Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO John F. Crowley sold 11,346 shares of the stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $8.00, for a total transaction of $90,768.00. Following the completion of the sale, the chief executive officer now owns 932,807 shares in the company, valued at approximately $7,462,456. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Amicus Therapeutics news, CEO John F. Crowley sold 10,468 shares of Amicus Therapeutics stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $8.01, for a total value of $83,848.68. Following the completion of the transaction, the chief executive officer now owns 922,339 shares in the company, valued at approximately $7,387,935.39. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO John F. Crowley sold 11,346 shares of the firm's stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $8.00, for a total value of $90,768.00. Following the completion of the sale, the chief executive officer now owns 932,807 shares of the company's stock, valued at $7,462,456. The disclosure for this sale can be found here. Over the last three months, insiders sold 130,779 shares of company stock valued at $1,237,966. 2.10% of the stock is currently owned by company insiders.

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock News Headlines

See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings
8/04/2022
Today
8/10/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
496
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$15.25
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+23.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-250,460,000.00
Pretax Margin
-85.15%

Debt

Sales & Book Value

Annual Sales
$305.51 million
Book Value
$1.10 per share

Miscellaneous

Free Float
274,608,000
Market Cap
$3.47 billion
Optionable
Optionable
Beta
0.96

Social Links















FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2022?

5 brokers have issued 1-year price targets for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $14.00 to $16.00. On average, they expect the company's share price to reach $15.25 in the next year. This suggests a possible upside of 23.4% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How has Amicus Therapeutics' stock price performed in 2022?

Amicus Therapeutics' stock was trading at $11.55 at the beginning of the year. Since then, FOLD shares have increased by 7.0% and is now trading at $12.36.
View the best growth stocks for 2022 here
.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. Amicus Therapeutics had a negative trailing twelve-month return on equity of 102.55% and a negative net margin of 87.50%. During the same quarter in the previous year, the business earned ($0.19) EPS.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $350.00 million-$365.00 million, compared to the consensus revenue estimate of $355.01 million.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.33%), Candriam S.C.A. (0.30%), Peregrine Capital Management LLC (0.28%), Integral Health Asset Management LLC (0.25%), Pictet Asset Management SA (0.23%) and Swiss National Bank (0.18%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $12.36.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.47 billion and generates $305.51 million in revenue each year. The biopharmaceutical company earns $-250,460,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 496 workers across the globe.

When was Amicus Therapeutics founded?

Amicus Therapeutics was founded in 2002.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.